Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
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
uAN1pAN1wKfDpEGu
Listen
